1.0Pharma Trendhttps://pharma-trend.com/enBusiness Wirehttps://pharma-trend.com/en/author/business/rich600338<blockquote class="wp-embedded-content" data-secret="qN4u5hcYXd"><a href="https://pharma-trend.com/en/veradigm-provides-2025-business-update/">Veradigm Provides 2025 Business Update</a></blockquote><iframe sandbox="allow-scripts" security="restricted" src="https://pharma-trend.com/en/veradigm-provides-2025-business-update/embed/#?secret=qN4u5hcYXd" width="600" height="338" title="“Veradigm Provides 2025 Business Update” — Pharma Trend" data-secret="qN4u5hcYXd" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"></iframe><script type="text/javascript"> /* <![CDATA[ */ /*! This file is auto-generated */ !function(d,l){"use strict";l.querySelector&&d.addEventListener&&"undefined"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i<o.length;i++)o[i].style.display="none";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute("style"),"height"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):"link"===t.message&&(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document); //# sourceURL=https://pharma-trend.com/en/wp-includes/js/wp-embed.min.js /* ]]> */ </script> CHICAGO–(BUSINESS WIRE)–Veradigm® (OTCMKTS: MDRX), a leading provider of healthcare data and technology solutions, is providing estimated financial performance for the second quarter of 2025 compared to the prior year, details about its recent financing activities, and reaffirmation of its outlook for the 2025 fiscal year. On Tuesday, September 2, longtime healthcare IT industry veteran Donald ... [Read more...]https://mms.businesswire.com/media/20250930147811/en/1867052/22/VeradigmR-logo.jpg